BIOMERICA

Investor Presentation

November 2024

Forward-Looking Statement

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this presentation (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, including statements not of historical fact; such as statements relating to - intended launch dates, sales potential, product benefits, market size, number of sufferers with IBS, prospects, new products, favorable outlook, market competition, anticipated or possible future revenues including InFoods® technology revenue opportunities, the regulatory pathway to FDA clearance, probability of FDA or other regulatory clearances, insurance reimbursement availability and amounts, physician adoption rates, efficacy and pricing of competing products, patent protection of the InFoods® technology, production volume of the Company’s products, and the launch or success of current and new product offerings; as well as statements relating to the Company’s products including; the efficacy of InFoods IBS at treating IBS symptoms in patients, accuracy of the InFoods product at detecting correct foods causing patient IBS symptoms, results of studies testing the Company’s products’ efficacy and accuracy, FDA clearance timing and requirements, EU clearance including CE Mark, the rapidity of testing results, uniqueness of these tests, use and commercial adoption of the Company’s tests, pricing of the Company’s test kits, domestic and international demand and orders, the Company’s manufacturing capacity, patent protection, and all regulatory approvals necessary prior to commercialization of the Company’s tests; and, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; competition from other similar products and from competitors that have significantly more financial and other resources available; and any other aspect of the Company’s tests and products. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Forward looking statements also include the assumptions underlying or relating to such statements. The underlying assumptions could prove to be inaccurate or known or unknown risks or uncertainties could materialize, therefore actual results could vary materially. The potential risks and uncertainties include, among others, fluctuations in the Company’s operating results, downturns in international and or national economies, the Company’s ability to raise additional capital as needed, the competitive environment in which the Company will be competing, and the Company’s dependence on strategic relationships and on regulatory approvals. A further list and description of these risks, uncertainties and other factors can be found in our report on Form 10-K filed with the Securities and Exchange Commission on August 29, 2022. Any forward-looking statements made in this presentation speak only as of the date of the presentation. The Company is under no obligation to update any forward-looking statements after the date of this presentation.

Who We Are

Depth of Scientific Leadership

US Members of the Rome Foundation Clinical studies lead by principal investigators who set GI “treatment guidelines”

Large-scale Device Manufacture

Production of products in GI and areas at 2 facilities



Global Biomedical Company

Develops, patents, manufactures & markets advanced diagnostics for use in Clinical lab, Point-of-Care, At-Home

Contract Manufacturer

For 2 multinational pharma companies, Bio-Rad & other leading organization

2 FDA, CE, CFDA registered manufacturing facilities in California and Mexico Headquarter: Irvine, CA, USA

Experienced Manufacturer of **FDA cleared & CE marked** products

Our customers in USA

MAYO CLINIC
Mayo Medical Laboratories

Quest Diagnostics

CVS/pharmacy
Expect something extra

Walmart

Walgreens
The Pharmacy America Trusts • Since 1901

BIOMERICA

Leadership, Board & Depth in Science

Management

ZACK IRANI-COHEN
- Chief Executive Officer & Chairman
- Previous CEO & Chairman of Lancer Orthodontics Inc.

ALLEN BARBIERI
- Executive Vice Chairman
- Previous CEO of numerous public and private companies

Independent BOD Members

Cathy Coste, CPA
Former Deloitte Partner

Jane Emerson, MD, PhD
Chief of Clinical Pathology, USC

David Moatazedi
CEO Evolus (NASDAQ: EOLS)

Scientific Advisory Board

DOUGLAS DROSSMAN, MD
- President Emeritus, Rome Foundation
- Co-Director Emeritus, UNC Center for Functional GI and Motility Disorders

LIN CHANG, MD
- Professor of Medicine, UCLA, Division of Digestive Diseases
- Rome Board member
- Served on FDA GI advisory panel

WILLIAM CHEY, MD, AGAF, FACG, FACP
- Professor GI & Nutrition Sciences, Univ. of Michigan
- Rome Board member
- Co-Director Michigan Bowel Program

BRIAN LACY, MD, PHD
- Mayo Clinic
- Co-Author of ACG Guidelines

ANTHONY LEMBO, MD
- Harvard Medical & Beth Israel Deaconess Medical Center
- Associate Editor of Journal of Clinical Gastroenterology and Digestive Diseases and Science

Principal Investigators or Collaborators for:

Linzess

Xifaxan

Linzess
Viberzi
Xifaxan

amitiza lubiprostone

Linzess
Viberzi

InFoods® Principal Investigators

WILLIAM CHEY, MD, AGAF, FACG, FACP
- University of Michigan – Ann Arbor
- Director of the Digestive Diseases Center
- Co-Author of ACG Guidelines

ANTHONY LEMBO, MD
- Harvard – Beth Israel Deaconess Medical Center

TISHA LUNSFORD, MD
- Mayo Clinic
- Director of the Motility Interest Group

BRIAN LACY, MD, PHD
- Mayo Clinic
- Current co-Editor in Chief of the American Journal of Gastroenterology
- Co-Author of ACG Guidelines

EAMONN QUIGLEY, MD
- Chief, Division of Gastroenterology and Hepatology at Houston Methodist

BROOKS CASH, MD, AGAF, FACG, FACP, FASGE
- Chief of Gastroenterology, University of Texas Health Science Center at Houston

University of Michigan Health System

HARVARD MEDICAL SCHOOL TEACHING HOSPITAL

MAYO CLINIC

MAYO CLINIC

Houston Methodist

UTHealth | McGovern Medical School

BIOMERICA

Background & Innovation

Leveraging diagnostic expertise to transition into diagnostic-guided therapeutics

Specialty diagnostics *enabling early disease detection and monitoring*

- Two FDA, CE, CFDA registered manufacturing facilities in California and Mexico
- Commercially launched FDA cleared diagnostic tests

Disruptive patented technology platform *enabling diagnostic therapies*

- Redefining the treatment of GI diseases
- Also applicable for treating non-GI chronic inflammatory diseases
- Gross margin opportunities similar to drugs

InFoods® – Diagnostic Guided Therapy (DGT) Personalize Medicine for IBS patients



- FDA-regulated diagnostic to be used as therapy
- Measures immunoreactivity for a panel of foods to determine which foods are above normal range and problematic for a specific patient
- Allows physicians to identify patient-specific foods which, when removed from diet, may alleviate or improve the patient's gastrointestinal symptoms and suffering
- Clinical trial guided by U.S. members of the Rome Foundation, the leading organization that sets IBS treatment guidelines

Note: Clinical lab product in clinical studies.

Example of Patient-Specific Results

LAB RESULTS

inFoods IBS
PRECISION MEDICINE FOR IBS

PATIENT NAME:	TESTLAST, TESTFIRST	**ORDER ID #:**	IBSTEST01	**PROVIDER NAME:**	Self Refer
DOB:	01-01-1960 AGE: 63 GENDER: F	**ACCESSION:**	V2211100027	**CLINIC NAME:**	Biomerica Inc
SPECIMEN TYPE:	Vial - Red Top	**RECEIVED DATE:**	01/27/2023	**CLINIC ADDRESS:**	17571 Von Karman Ave
COLLECTED DATE:	01/26/2023	**REPORT DATE:**	11/10/2022	**PHONE:**	949-379-2874

About this test

The patented inFoods® IBS test panel is designed to identify foods that cause an elevated immune response (foods with an elevated IgG level) in patients with irritable bowel syndrome (IBS). In a clinical study, patients who removed positive foods from their diet experienced reduced symptoms of IBS including pain and bloating, as well as an improvement in overall feelings of wellbeing. Discuss the results of this test and any treatment plans with your healthcare provider.

1 What your results mean:

POSITIVE FOODS: When compared to patients without IBS, your immune response (IgG immunoreactivity) is ELEVATED above a normal level for this food.

NEGATIVE FOODS: When compared to patients without IBS, your immune response (IgG immunoreactivity) is at a NORMAL level for this food.

POSITIVE FOODS

Rye ELEVATED IgG LEVEL	Cow's milk ELEVATED IgG LEVEL	Cocoa ELEVATED IgG LEVEL	Orange ELEVATED IgG LEVEL

NEGATIVE FOODS

Corn NORMAL IgG LEVEL	Oat NORMAL IgG LEVEL	Wheat NORMAL IgG LEVEL	Whole Egg NORMAL IgG LEVEL	Pineapple NORMAL IgG LEVEL

BIOMERICA

Irritable Bowel Syndrome (IBS) is Very Common and Costly

IBS is the **#1 most common diagnosis** made by gastroenterologists[1]

IBS is the **#7** most common diagnosis made by **all physicians**[1]

IBS patients visit doctors **3x more** than non-IBS patients

IBS sufferers have **74% more** direct healthcare costs vs. non-IBS sufferers

The Majority of IBS patients believe **foods trigger** their **symptoms**

[1]Recent AGA Survey (American Gastroenterological Association).

BIOMERICA

IBS Market is Significant Today and Growing

$30B+

U.S. TAM[1]



40 Million
IBS Patients in the US

1/3 IBS-C (Constipation)

1/3 IBS-D (Diarrhea)

1/3 IBS-M (Mixed: Alternates C+D)

IBS = recurrent abdominal pain & change in bowel habits

~16 MILLION **US IBS Patients:** seeking consistent physician treatment

~13 MILLION **IBS-M Patients:** No approved therapy/drug[2]

[1]Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. *Clinical gastroenterology and hepatology*. 2012 Jul 1;10(7):712-21.
[2]Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. *Alimentary pharmacology & therapeutics.* 2005 Jun;21(11):1365-75.

BIOMERICA

Clinical Study

Clinical Study of InFoods IBS[1]

- **Study Sites:** Mayo Clinic, Harvard Beth-Israel, Univ. Michigan, Univ. Texas Houston
- **Study Design:** 8-week, prospective, double-blinded, placebo-controlled, randomized, multi-center
- **Treatment Arm:** True Diet - Elimination of positive foods (above normal levels of IgG) from the diet of IBS patients
- **Placebo Arm:** Sham Diet – Elimination of non-positive foods from the diet of IBS patients

238 IBS Patients were randomized into the trial



82 IBS-D	41 True Diet 41 Sham Diet
84 IBS-C	44 True Diet 40 Sham Diet
72 IBS-M	38 True Diet 34 Sham Diet

- Mean Age: **41**
- **21.5%** Male
- **78.5%** Female
- **93.4** mean number of months treated for IBS prior to enrollment

[1]Endpoint Determination Study for An Antibody Guided Dietary Restriction Trial Using Biomerica InFoods® IBS Test in Patients With a Previous Diagnosis of Irritable Bowel Syndrome (IBS) (NCT03459482)

InFoods® IBS: Clinical Trial Design Summary



Highlights

Statistically meaningful improvements were seen in multiple endpoints (symptoms), this is only a selection of topline results from the InFoods® IBS endpoint trial

Global Endpoints

SGA

GIS

InFoods® IBS
Top Line - Global Endpoints

inFoods **Treatment Arm** **Vs.** **Placebo Arm**

P-value of 0.007 for improvement in the **Subject's Global Assessment of Relief (SGA)** endpoint for all patient subtypes as a group (baseline vs 8 weeks)

Subject's global assessment (SGA) of relief is a single measure (endpoint) encompassing abdominal pain/discomfort, altered bowel function, and overall well-being. This measure, which has been validated in populations with IBS, was considered the standard assessment of symptoms for IBS trials in the past[1]

P-value of 0.040 for improvement in the **Global Improvement Scale (GIS)** endpoint for all patient subtypes as a group (baseline vs 8 weeks)

Global Improvement Scale (GIS) assesses multiple irritable bowel syndrome (IBS) symptoms using a patient-defined 7-point Likert scale ranging from symptoms substantially worse to substantially improved

1. Aliment Pharmacol Ther 2001;15:1655–66 & Gastroenterology 2000;118:A145

BIOMERICA

Highlights

Statistically meaningful improvements were seen in multiple endpoints (symptoms), this is only a selection of topline results from the InFoods® IBS endpoint trial

Pain and Bloating

API

Bloating

InFoods® IBS
Top Line - Global Endpoints

inFoods Treatment Arm **Vs.** **Placebo Arm**

P-value of 0.012 for improvement in the **Abdominal Pain Intensity (API)** endpoint for IBS-Mixed & IBS-Constipation patients as a group (baseline vs 8 weeks)

IBS is partly defined by pain, and pain is the cornerstone of the IBS illness experience for many patients. Abdominal Pain Index (API) is the only instrument that can be scored as a composite measure of overall abdominal pain severity composed of pain frequency, intensity, and duration[1]

P-value of 0.022 for improvement in the **Bloating** endpoint for IBS-Mixed & IBS-Constipation patients as a group (baseline vs 8 weeks)

Bloating is reported by up to 96% of patients with irritable bowel syndrome (IBS), is more common in females, and is often ranked as their most bothersome symptom[2]

1. J Pediatr Psychol. 2015 Jun; 40(5): 517–525 & Aliment Pharmacol Ther. 2010 Nov; 32(9): 1192–1202.
2. Gastroenterology Volume 131, Issue 4, P1003-1010, October 2006

BIOMERICA

FDA Approved Drugs are Expensive and have Efficacy and Safety Limitations

Indication	Drug	FDA Approval	Treatment Response	Placebo Response	Efficacy: Treatment minus Placebo	Monthly Cost	Annualized U.S. Sale	Limitations
IBS-C	**Linzess**	2012	20% - 34%	6% - 27%	**7% - 14%**	$467	$1,963M	• Diarrhea side effect (20%)
	Amitiza	2008	14%	8%	**6%**	$371	$410M	• Indicated for women only; not for men
IBS-D	**Xifaxan**	2015	41%	32%	**9%**	$2,757[1]	$1,905M	• Not for chronic use
	Viberzi	2015	25% - 30%	17% - 16%	**8% - 14%**	$1,383	$266M	• Abdominal pain (secondary) endpoint not met
	Lotronex	2002	NA	NA	**13% - 20%**	$2,240[2]	$6M	• For women only • Black box warning
IBS-C IBS-D IBS-M	**InFoods**	LDT launch	58% 58%	48% 43%	**10% to 15%**	N/A	New	• No side effects • 10% all patients • 15% women only

IBS Drug Side Effects Can Be Dangerous | **Lotronex carries a black box warning related to the risk of potentially serious GI events**

[1]Denotes cost for 550mg Xifaxan dose; 200mg dose WAC is $723. [2]Denotes cost for 1mg Lotronex dose; 0.5mg dose WAC is $1,120.
Source: IQVIA FY2020 sales and monthly WAC.

Abdominal Pain Index (API) Change from Baseline
IBS non-D Population





Linear Mixed Model
Wk 8 P-Value 0.0139

InFoods® Regulatory & Commercial Pathway

- CLIA Lab Developed Test to be launched on fiscal Q3
- FDA has determined proposed IBS clinical study is **a non-significant risk** → De Novo
- Recently competed Endpoint Trial results driving significant interest from physician groups

Endpoint and Pivotal Trials Overview

Sites

Mayo Clinic, **Harvard BID, University of Michigan, Houston Methodist, University of Texas Houston & others**

Design

Double-blind randomized placebo controlled trial of true diet for foods with a positive immune response v. sham diet of random foods

Primary Endpoint

All 9 FDA endpoints QOL, API, BSS, SSS, etc. for Endpoint Trial; one endpoint to be selected for Pivotal Trial (e.g. API)

Participants

N=180 (Endpoint Trial); N=500-700 (Expected for Pivotal Trial)

Complete

Completed Endpoint Clinical Trial shows improvements in Multiple Symptoms for IBS Patients

Launch of InFoods IBS as LDT with Gastro Health

New Relationship with Gastro Health (GH):

A leading gastroenterology group with over **390 employed GI physicians**. A leader in advanced innovation and technology in GI patient care .

Operates over 100 patient care centers in Alabama, Florida, Maryland, Massachusetts, Ohio, Virginia, and Washington.

InFoods IBS is now integrated into GH patient systems to facilitate doctors' **"one click" ordering** for the inFoods IBS test.

New Groups Recently Added:

Integrated medical system that employs approximately 7,500 medical staff

The large GI group has over 90 physicians in 60 locations and offers advanced treatment options for GI diseases.

Pilot

Pilot of inFoods® IBS with Large 1,100 Physician Group

InFoods IBS: Whole Blood

inFoods® IBS: Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology

Finger stick (capillary) patient whole blood samples simplify sample collection and facilitate wider access to the test.

Any trained medical professional in the doctor's office can collect the patient's blood sample during their office visit and forward the sample to the Lab for processing.

This workflow enhancement greatly simplifies the process for healthcare providers to order the inFoods IBS test and is much easier for patients

BIOMERICA

At Home Collection & Workflow

- Simple At-Home Self Collection
- Return shipping (USPS) label included in kit
- Simple Instructions and video
- Quick Turnaround 2 to 3 weeks

Patient pays for test → Lab to ships kit to customer (or NP hands kit to patient) → Patient receives kit, self collects sample & returns sample to lab → Lab receives, processes and reports results

BIOMERICA

InFoods® IBS: Broad Benefits to Patients, Physicians, and Healthcare Insurers

Targets 100% of the IBS Market (IBS-M, IBS-C, IBS-D)[1]

Patient Benefits

InFoods® targets underlying causes **without causing side effects**

VS

IBS Drugs – Primarily treat symptoms AND can cause **major side effects**

Physician Benefits

InFoods®: Recurring revenue potential as problem foods change in patients

VS

IBS Drugs = $0 revenue to physician

Payer/insurer Benefits

InFoods® insurer savings
Currently: IBS Patients require 3x doctor visits & monthly drug costs

U.S. Healthcare annual costs of IBS ~$30B/year

[1]IBS-M = Mixed: Alternates C+D; IBS-C = Constipation; IBS-D = Diarrhea.

BIOMERICA

InFoods® Commercialization Strategy

Multiple Avenues to Drive Adoption

Inclusion in Guidelines

- Inclusion in the IBS treatment guidelines will accelerate product adoption
- The Rome Foundation holds significant influence in setting the treatment guidelines
- InFoods IBS will be presented in the IBS clinical session at 2024 DDW

Reimbursement Awareness and Enhanced Coverage

- Help GI physicians monetize their largest patient population: reimbursement code already exists for Medicare patients
- Initiate conversations with payors to enhance access to product at both the point of care and outpatient diagnostic centers

Broad Physician Interest

- Capitalize on strong physician interest evidenced by market research[1]
- GI physician and PCP respondents indicated they would adopt this product for 95% - 100% of their patients, depending on the IBS subtype[1]

95% GI Physicians and PCPs Would Adopt InFoods® for Their Patients Depending on Subtype

[1]Market Research Source: Market Vision. Percentages shown represent medians for both GI physicians and PCPs based on the information they were presented as part of the market research survey.

BIOMERICA

SAB: Rome Foundation-Sets IBS Guidelines Expertise in Clinical Trials

Rome Foundation
(Leading IBS organization)

- Leading independent non-profit organization focused on the diagnosis and treatment of functional gastrointestinal disorders, including IBS
- Rome creates the diagnostic criteria and guidelines that FDA and physicians use to define an IBS patient, and treat those patients

Dr. Doug Drossman
(Biomerica SAB Chair)

- Dr. Doug Drossman (President Emeritus of the Rome Foundation) is one of the foremost opinion leaders in IBS
  - Participated in 50+ Clinical Studies for IBS

Key Expertise on IBS Clinical Trials

- SAB members were the PI's on clinical trials for multiple approved GI drugs, including Linzess®, Viberzi®, and Xifaxan®
- Members serve on FDA GI advisory panel



Platform Technology:

InFoods®
Development Pipeline

		IP & Data	Product Dev. R&D	FDA Sub Q	End Point Trial	CLIA LDT Launch	Pivotal Trial & FDA Approval
Functional Gastrointestinal Disorders	20 Foods	Irritable Bowel Syndrome (IBS)					
	37 Foods	Functional Dyspepsia					
	19 Foods	GERD disease					
Gastrointestinal Diseases	58 Foods	Ulcerative Colitis (UC)					
	79 Foods	Crohn's					
Other Chronic Inflammatory Diseases	52 Foods	Migraines					
	59 Foods	Psoriasis					
	26 Foods	Depression					

BIOMERICA

Specialty Diagnostics





2024 Growth opportunity - H. pylori

hp detect™

Detects H. pylori Antigen

H. pylori is a bacteria that infects approximately 35% of the U.S. population and 45% of the population in the five major countries in the Europe. Approximately 20% of *H. Pylori* infected patients develop a range of issues including peptic ulcer disease, dyspepsia and gastric cancer.

Status: Biomerica received **FDA 510K clearance**

Gastric Cancer: Gastric cancer is the 3rd most common cause of cancer related death in the world. Over 80% of gastric cancers are attributed to *H. pylori* infection. In 2017, the World Health Organization (WHO) listed *H. pylori* among the 16 antibiotic-resistant bacteria that pose the greatest threat to human health and designated *H. pylori* as a Class 1 carcinogen.

Profit Opportunity: Biomerica H. pylori product has clinical and economic benefits while being able to be sold at a significant discount to competitive products.

Customers: The majority of H. pylori diagnostic tests are sold to large labs such as Quest, LabCorp and ARUP. Therefore, less marketing effort is needed to achieve material market penetration.

Colorectal Disease Test: EZ Detect™

EZ Detect is a 2-minute, at-home test for the determination of fecal occult blood, an early warning sign of colorectal cancer (CRC) and other colorectal diseases.

Quick & Simple:

No Stool Handling



Interpretation

Negative	Positive	Positive

Any color in the test area (no matter how small) should be considered as a positive result

BIOMERICA

Key performance metrics for EZ Detect™, Cologuard®, & FITs

Value	EZ Detect™ (1)	Cologuard® (2)	FIT (2)
Price	$14	$649	$22
Accuracy	93.2%	86.6%	94.7%
Positive Likelihood Ratio	91.2	6.9	14.3
Negative Likelihood Ratio	0.27	0.09	0.28
Specificity (vs. all negative findings on colonoscopy/sigmoidoscopy)	99.2% (124/125)	86.6% (7936/9167)	94.9% (8,695/9167)
Sensitivity (vs. all CRC found by colonoscopy/sigmoidoscopy)	72.9% (27/37)	92.3% (60/65)	73.8% (48/65)
Negative Predictive Value	92.5% (124/134)	99.9% (7936/7941)	99.8% (8695/8712)
Positive Predictive Value	96.4% (27/28)	4.6% (60/1291)	9.2% (48/520)



(1)Results of the Study (Screening) Conducted by Renfe's Medical Department. 2000.
(2)Multitarget Stool DNA Testing for Colorectal-Cancer Screening. Imperiale, Thomas F, et al. 2014, The New England Journal of Medicine, Vol. 370, pp. 1287-1297.

BIOMERICA

Aware® Breast Self Exam

- **FDA – Cleared and CE Mark**
- The Aware® Pad is as an aid for performing at-home breast self-examination
- About **80% of breast cancers** are **detected because women themselves notice changes** in their breasts[1]
- Recurrent purchases and several pads for female family members



1. https://www.pinkribbon-deutschland.de/vorsorge-fakten/fakten, accessed 02 AUG 2022

Aware® Performance

Clinical Study
Kawasaki Medical University Hospital
for Aware FDA approval (N=832 Patients)

- Study concluded that **Aware®** is a highly effective tool for early detection of breast abnormalities
- Regular practice of Breast Self Exam is extremely important for early cancer detection

Detection Ratios				
	Breast Cancer	**Fibroma** Biopsy Case / Non-Biopsy Case	**Mastitis** Biopsy Case / Non-Biopsy Case	**Non-Tumor**
Patient	98.6%	90.9%/87.8%	86.4%/65.2%	9.8%
Nurse	100%	96.0%/92.0%	86.4%/58.2%	4.8%

Prostate (PSA) Screening Test

- The Fortel® Prostate (PSA) Screening test is a simple at-home visual test to **detect elevated levels of Prostate Specific Antigen (PSA)** using a finger prick blood sample
- Laboratory accuracy in the comfort of your home
- Results in 10 minutes

Prostate (PSA) screening made easy.

Laboratory Accuracy

Clinical Study #1
Performance vs. Reference Method (Immulite 2000/ Abbott Axsym Total PSA /Roche E170 tests)

Sensitivity:	**100%**
Specificity:	**95%**
Accuracy:	**97.5%**

		Reference Method		
Fortel® Prostate (PSA) Screening Test		**Positive**	**Negative**	**Total**
	Positive	80	4	84
	Negative	0	77	77
	Total	80	81	161

- Clinical studies for PSA were performed using 161 clinically confirmed samples.



Insurance reimbursement & distribution

New multi-year exclusive distribution agreement with leading UAE healthcare company recently signed

Dubai Government Grants Insurance Reimbursement for EZ Detect

In discussions with other governments for Insurance Reimbursement in UAE and other MENA countries

Fortel® Prostate PSA received approval from the Kingdom of Saudi Arabia

Leveraging Our Unique Technology

Disruptive Patented Platform Technology redefining the GI Market

Addressing the large need for IBS patients and then targeting multiple other diseases

InFoods Model is Unique

Benefits Patient / Physician / Insurer

Broad IP Protection

Robust patent portfolio (35 issued patents; 100+ patents pending)

- 15+ year remaining on patents filed
- Patents cover multiple disease states

Financially Attractive

- Low burn rate
- Clean Cap table - No warrants, no preferred equity and no debt

IBS Key Opinion Leaders set Treatment Guidelines

- SAB Leadership includes US Members of the Rome Foundation
- Clinical studies lead by principal investigators who set GI “treatment guidelines”

BIOMERICA